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A Deleterious Mutation in SAMD9 Causes Normophosphatemic
Familial Tumoral Calcinosis
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Mordechai Choder, Dani Bercovich, Jouni Uitto, Reuven Bergman, Gabriele Richard,
and Eli Sprecher
Familial tumoral calcinosis (FTC) is a rare autosomal recessive disorder characterized by the progressive deposition of
calcified masses in cutaneous and subcutaneous tissues, which results in painful ulcerative lesions and severe skin and
bone infections. Twomajor types of FTC have been recognized: hyperphosphatemic FTC (HFTC) andnormophosphatemic
FTC (NFTC). HFTC was recently shown to result from mutations in two different genes: GALNT3, which codes for a
glycosyltransferase, and FGF23, which codes for a potent phosphaturic protein. To determine the molecular cause of
NFTC, we performed homozygosity mapping in five affected families of Jewish Yemenite origin and mapped NFTC to
7q21-7q21.3. Mutation analysis revealed a homozygous mutation in the SAMD9 gene (K1495E), which was found to
segregate with the disease in all families and to interfere with the protein expression. Our data suggest that SAMD9 is
involved in the regulation of extraosseous calcification, a process of considerable importance in a wide range of diseases
as common as atherosclerosis and autoimmune disorders.
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Extraosseous calcification is considered to play a pivotal
role in the pathogenesis of a wide range of common dis-
orders, such as atherosclerosis and renal failure.1,2 Recent-
ly, the deciphering of the genetic basis of a number of rare
monogenic hereditary syndromes has shed light on the
molecular mechanisms regulating this process.3
Familial tumoral calcinosis (FTC) is an uncommon life-
threatening disorder characterized by massive periarti-
cular—and seldom visceral—deposition of calcified tu-
mors.4 When associated with hyperphosphatemia, the
disease is known as “hyperphosphatemic FTC” (HFTC
[MIM #211900]) and can result frommutations in at least
two genes: GALNT3, which encodes the glycosyltrans-
ferase UDP-N-acetyl-a-D-galactosamine:polypeptide N-
acetylgalactosaminyl transferase 3 (ppGalNacT3) that is
responsible for initiating O-glycosylation, and FGF23,
which encodes a potent phosphaturic protein.5–12 Re-
cent data suggest that FGF23 extracellular secretion may
depend on ppGalNacT3-mediated O-glycosylation.13 A
bone disorder termed “hyperostosis-hyperphosphatemia
syndrome” (MIM #211900) was also shown to result from
mutations in GALNT3.14 To complicate the picture even
further, we identified a subset of patients with FTC who
display normal circulating levels of phosphate. These in-
dividuals were found not to carry mutations in GALNT3
or FGF23, which suggests that HFTC and normophospha-
temic FTC (NFTC) are nonallelic.5 In the present study, we
identified a deleterious mutation in SAMD9 that underlies
NFTC in five affected families.
All participants or their legal guardians providedwritten
and informed consent, according to a protocol approved
by the local Helsinki Committee and by the Committee
for Genetic Studies of the Israeli Ministry of Health. Blood
samples were drawn from all family members, and DNA
was extracted according to standard procedures. Skin bi-
opsy samples were fixed in formaldehyde. Fibroblast cell
cultures were established from punch-skin biopsy samples
from patients or healthy control individuals, and were
maintained in Dulbecco’s modified Eagle medium supple-
mented with 10% fetal calf serum.
We assessed a total of eight individuals affected with
NFTC from five families of Jewish Yemenite origin (fig. 1a).
All patients reported reddish-to-hyperpigmented skin le-
sions during the 1st year of life (fig. 2a), which preceded
the later appearance of calcified nodules, distributedmain-
ly over the extremities (fig. 2b). In addition, severe con-
junctivitis and gingivitis (fig. 2c) were observed in most
of the affected individuals. Results of routine laboratory
tests—including calcium, phosphate, vitamin D3metabo-
lites, and parathyroid-hormone levels—were normal. His-
topathological examination of lesional skin biopsies dis-
closed massive calcium deposition in the mid- and lower
dermis (fig. 2d).
Because all families shared a common ethnic origin and
since NFTC is a very rare condition, we postulated the
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Figure 1. NFTC maps to 7q21-7q21.3. a, Haplotype analysis of five NFTC-affected families, through use of polymorphic markers on
chromosome 7q21. Blackened symbols represent affected individuals. The disease-associated haplotype found in the five families is
boxed in red. b, Multipoint linkage analysis, which generated a maximum LOD score of 3.4 between markers D7S2409 and D7S623.
existence of a single homozygous causative mutation and
thus used homozygosity mapping to locate the NFTC gene.
We performed a genomewide marker screen, using fluo-
rescently labeled primer pairs spanning 731 microsatel-
lite loci (369 markers obtained from PE Biosystems and
362 markers obtained from Research Genetics/Invitrogen)
in five affected individuals. We initially identified a 7.6-
Mb homozygous interval on 7q21-7q21.3 that was shared
by all five patients (not shown). Subsequently, genotypes
were obtained for all family members at seven additional
microsatellite loci across this region (fig. 1a). Multipoint
analysis (with use of Superlink software [Genetic Linkage
Analysis Project], as described by Silberstein et al.15) gen-
erated a maximum LOD score of 3.4 between markers
D7S2409 andD7S623 (fig. 1b). Haplotype analysis revealed
a critical recombination event in individual 7 between
markers D7S2410 and D7S2409 and a diverging haplotype
in patient 15 at marker D7S2430, thereby establishing the
centromeric and telomeric boundaries of the disease-as-
sociated interval (fig. 1a).
Of 23 genes contained within this interval (Map Viewer
[build 36]), we excluded PEX1, since mutations in this gene
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Figure 2. Clinical features of NFTC—including heralding erythematous papular eruption (a), small calcified tumors ulcerating and
discharging chalk-like materials on the surface of the skin (b), and severe gingivitis (c)—and calcified material in the upper dermis,
as revealed by histopathological examination (d).
have been shown to cause peroxismal disorders.16 Twenty-
two genes were analyzed for pathogenic mutations by di-
rect sequencing (primer pairs and PCR conditions avail-
able on request) of all coding regions, as well as exon-
intron boundaries in one or two affected individuals.Only
two single-nucleotide substitutions were found to segre-
gate with the disease phenotype in all families. An ArG
transition at cDNA position 409 of MGC40405, which
codes for a protein of unknown function and results in a
valinermethionine substitution, was found in 6% of the
general Israeli population (4 of 68 healthy controls). The
second mutation is an ArG transition at cDNA position
4483 of SAMD9 (fig. 3a), which is predicted to result in
the substitution of a negatively charged glutamic acid res-
idue for a positively charged lysine residue at amino acid
position 1495 of the protein sequence. To screen for this
mutation, we amplified a 115-bp fragment, using reverse
primer 5′-GCAATATAAACATATGCATCGTAC-3′ and allele-
specific forward primer 5′-CTTCTTAAAGCACTGGTCAAT-
TTTTTC-3′; the latter creates a recognition site for endo-
nuclease MboII (fig. 3b). Using this assay, we confirmed
cosegregation of the mutation with NFTC in all families
and excluded the mutation from a panel of 1,042 control
chromosomes derived from blood samples obtained from
healthy individuals of Jewish origin. We then screened 92
healthy, unrelated Jewish individuals born to couples who
immigrated to Israel from Yemen. One individual in this
cohort was found to carry both K1495E and the disease
haplotype in a heterozygous state, which corresponds to
a carrier rate of ∼0.01, fitting the expected prevalence of
the disease in the Israeli Jewish Yemenite population.
SAMD9 encodes a 1,589-aa protein of unknown func-
tion and is expressed in a wide range of tissues, including
skin (fig. 3c). Quantitative real-time PCR revealed that the
gene is strongly expressed in endothelial cells and, to a
lesser degree, in fibroblasts (not shown).Moreover, SAMD9
mRNA expression level was found to be sixfold higher in
fibroblasts derived from patients with NFTC than in those
from healthy controls, which suggests compensatory up-
regulation of this gene by a currently unknown mech-
anism (fig. 3d).
Apart from an N-terminal sterile alpha motif (SAM), a
widely distributed putative protein interaction domain,17
SAMD9 bears very little homology to other known pro-
teins, except for a paralogous protein termed “SAMD9L”
(SAMD9-like), with which it shares 58% identity at the
amino acid–sequence level. K1495 seems to be well con-
served across species, suggesting that it is of physiological
importance (fig. 3e).
To determine the functional consequences of K1495E
mutation in SAMD9, a full-length SAMD9 cDNA was fused
to the green fluorescent protein (GFP) sequence in Gate-
way pDEST53 vector (Invitrogen) and was transfected into
HEK293 cells. Confocal microscopy demonstrated clear
punctate cytoplasmic expression of the GFP-SAMD9 fu-
sion protein. We then introduced the K1495E mutation
762 The American Journal of Human Genetics Volume 79 October 2006 www.ajhg.org
Figure 3. NFTC caused by a mutation in SAMD9. a, Sequence analysis of SAMD9 reveals an ArG transition at cDNA position 4483 in
patient 3 (left panel). The father of the patient carries the mutation in a heterozygous state (middle panel). The wild-type sequence
is given for comparison (right panel). b, PCR-RFLP analysis, which confirms segregation of the mutation in family 4. PCR amplification
was performed as described in the text. Mutation K1495E creates a novel recognition site for MboII. Thus, affected patients display a
93-bp fragment (an additional 22 bp not shown), and healthy individuals show a 115-bp fragment, whereas both fragments are found
in heterozygous carriers of the mutation. c, SAMD9 gene expression assessed using Clontech tissue blot cDNA array and using total
RNA extracted from skin biopsy samples obtained from healthy individuals. Expression of SAMD9 was compared with that of ACTB. d,
RNA was extracted from fibroblast-cell cultures established from two patients with NFTC and two healthy control individuals. SAMD9
mRNA expression, normalized to that of ACTB, was found to be up-regulated in NFTC fibroblasts (blue column) as compared with normal
fibroblasts (orange column). e, ClustalW analysis of the SAMD9 protein region encompassing the mutation site, which demonstrates
that K1495 is conserved across species. f, HEK293 cells transfected with wild-type (WT) (left panel) and E1495-carrying (right panel)
GFP-SAMD9 constructs and examined using confocal microscopy. Note decreased expression in cells transfected with E1495-carrying
GFP-SAMD9. MUT p mutant.
into the GFP-SAMD9 cDNA construct, using site-directed
mutagenesis (QuikChange JXL Site-Directed Mutagenesis
Kit [Stratagene]) according to the manufacturer’s instruc-
tions. SAMD9 mRNA levels were shown, by quantitative
RT-PCR, to be 4.8-fold higher in HEK293 cells transfected
with mutant SAMD9 than in cells transfected with wild-
type SAMD9. In seven independent experiments, we ob-
served that K1495E causes loss of punctate expression of
the fusion protein after transfection into HEK293 cells,
which indicates that this mutation interferes with SAMD9
expression (fig. 3f).
Collectively, the present data indicate that SAMD9 may
play a crucial role in the pathogenesis of extraosseous cal-
cification; yet, the detailed mechanisms of action of this
protein remain to be determined. The conspicuous in-
flammatory manifestations reported in NFTC,4 which are
absent in HFTC,5 suggest that this proteinmay be involved
in physiological responses to tissue injury.
At this stage, it seems that NFTC represents a clinical
entity found specifically in the Jewish Yemenite popula-
tion. This should not come as a surprise, since it is well
known that cultural isolation favors the emergence and
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clustering of unique genetic alterations, as shown else-
where for this community.18 In spite of the apparent rarity
of NFTC, it encompasses clinical features of relevance to
the understanding of important and common disorders.
Indeed, two major types of acquired skin calcinosis have
been described: (1) metastatic calcinosis, which refers to
deposition of calcified materials due to abnormal calcium
or phosphate metabolism, as seen in chronic renal failure,
and (2) dystrophic calcinosis, in which tissue calcification
occurs as a consequence of tissue injury/inflammation, as
observed in many unrelated conditions, such as vascular
disease, cancer, and autoimmune disorders.19–21 Whereas
HFTC models metastatic calcinosis, NFTC bears striking
resemblance to acquired dystrophic calcinosis. A growing
body of evidence links tissue inflammation to vascular
calcification, a major cause of morbidity and mortality in
humans.22,23 These observations raise the possibility that
alterations in SAMD9 expressionmay underlie the varying
occurrence of dystrophic calcinosis in a spectrum of hu-
man diseases.
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